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Abstract
Background: Radiographical features associated with a favourable response to trans-arterial chem-
oembolization (TACE) are poorly defined for patients with hepatocellular carcinoma (HCC).
Methods: From 2008 to 2012, all first TACE interventions for HCC performed at the University of
Alabama at Birmingham (UAB) were retrospectively reviewed. Only patients with a pre-TACE and a
post-TACE computed tomography (CT) scan were included in the analyses (n = 115). HCC tumour
response to TACE was quantified via the the modified Response Evaluation Criteria in Solid Tumors
(mRECIST) criteria. Univariate and multivariable analyses were constructed.
Results: The index HCC tumours experienced a > 90% or complete tumour necrosis in 59/115 (51%)
of patients after the first TACE intervention. On univariate analysis, smaller tumour size, peripheral
tumour location and arterial enhancement were associated with a > 90% or complete tumour necrosis,
whereas, only smaller tumour size [odds ratio (OR) 0.62; 95% confidence interval (CI) 0.48, 0.81] and
peripheral location (OR 6.91; 95% CI 1.75, 27.29) were significant on multivariable analysis. There was a
trend towards improved survival in the patients that experienced a > 90% or complete tumour necrosis
(P = 0.08).
Conclusions: Peripherally located smaller HCC tumours are most likely to experience a > 90% or
complete tumour necrosis after TACE. Surprisingly, arterial-phase enhancement and portal venous-phase
washout were not significantly predictive of TACE-induced tumour necrosis. The TACE response was not
statistically associated with improved survival.
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Introduction
Trans-arterial chemoembolization (TACE) is a common onco-
logical intervention in the treatment of hepatocellular carcinoma
(HCC). There has been much debate over the efficacy of TACE
prompting numerous survival studies with conflicting results. A
commonly referenced meta-analysis of prospective randomized
trials assessing TACE performed by Llovet et al. demonstrated a
significantly improved 2-year survival compared with best sup-
portive care.1 These data have served as the basis of the American
Association for the Study of Liver Disease (AASLD) practice
guideline that ‘TACE is recommended as first line non-curative
therapy for non-surgical patients . . .’2,3 Population-based data
demonstrates that TACE is the most common oncological treat-
ment performed for HCC in Medicare patients in the US.4 Review
of the Scientific Registry of Transplant Recipients (SRTR) data on
liver transplantation for HCC also demonstrates that TACE is the
most common bridging therapy offered to > 70% of waitlisted
patients in the US.5
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Clinical studies have focused on the survival benefit of
TACE with secondary outcomes being tumour necrosis quanti-
fied via the Response Evaluation Criteria for Solid Tumors
(RECIST).6 Studies demonstrate a correlation between HCC
tumour response to TACE and survival.7–9 However, there is little
clinical data identifying pre-intervention cross-sectional radio-
graphical tumour features that predict TACE-induced HCC
tumour necrosis. The purpose of this study was to measure the
association of pre-TACE computed tomography (CT) radio-
graphical characteristics on post-TACE tumour necrosis. The
primary endpoints for this study were modified (m)RECIST
quantification of tumor necrosis and overall survival. Our
hypotheses are (i) single tumours, smaller tumour size, periph-
eral tumour location, arterial-phase tumour enhancement and
portal venous-phase tumour washout will be associated with a
> 90% or complete HCC tumour necrosis, and (ii) patients with
a > 90% or complete HCC tumour necrosis will experience
improved survival compared with patients with < 90% tumour
necrosis, stable or progressive disease.
Methods
Ethics approval for this study was obtained from the University of
Alabama Institutional Review Board (Protocol no. X100310006).
A retrospective chart review was performed for all patients receiv-
ing a TACE at the University of Alabama at Birmingham (UAB)
between January 2008 and June 2012. Patients were identified
from an internal TACE database that is used for clinical purposes.
Patient population
Patients were diagnosed with HCC by biopsy or by the presenta-
tion of classic HCC radiological features of a >2 cm hypervascular
lesion arising in the setting of cirrhosis with arterial phase
enhancement and portal venous phase washout.10 The decision to
offer TACE to patients with HCC was made by a multi-
disciplinary board at UAB including medical oncologists, sur-
geons, hepatologists and interventional radiologists. Candidacy
for TACE was established using AASLD practice guidelines.2,3
Select Child’s B and Child’s C cirrhotic patients were also offered
TACE if they had an ECOG functional status of 0 or 1, had limited
tumour burden and their decompensation symptoms were well
controlled medically.
A list of all patients treated with TACE between January 2008
and June 2012 was generated from the UAB Interventional Radi-
ology procedures electronic database. (Fig. 1) HCC tumours that
had previously been treated with another loco-regional therapy
such as radiofrequency ablation or external beam radiotherapy
were excluded. Patients taking chemotherapeutic agents before
and after the procedure were not excluded. HCC patients were
only included if they had CT imaging within 75 days prior to the
TACE procedure and follow-up imaging within 75 days after the
TACE procedure.
CT technique
Threephase (unenhanced,arterial andportal venousphases) or four
phase (unenhanced, arterial, portal venous and delayed phases) CT
imaging were performed through the liver. All examinations were
performed with a multi-detector row helical CT scanner with the
following parameters: 120 kVp, 170–300 mAs (using automated
dose modulation) and gantry rotation time of 0.5 s. The first phase
was obtained without intravenous contrast. The contrast dose was
calculated based on the patient’s weight and renal function and was
injected at a rate of 4 ml/s. The timing of the subsequent phases was
based on bolus tracking which triggered when the region of interest
(descending aorta) reached150HU.MultiphasicCT scanswere then
obtained at 15 s (arterial phase), 45 s (portal venous phase) and
3–5 min (delayed phase) post trigger.
CT HCC tumour assessment and post-TACE
mRECIST tumour necrosis quantification
After an extensive training period, two second year medical stu-
dents (M.B. and D.D.) independently reviewed CT studies per-
formed before and after TACE for all patients. The body radiology
fellow (J.Z.) taught the medical students about the basics of mul-
348 TACE procedures
performed at UAB
from Jan 2008 to June
2012
45 TACE procedures on non-HCC
tumours excluded
303 TACE procedures
for HCC tumours
113 2nd – 5th TACE episodes excluded
190 1st TACE episode
for HCC patients
–23 no clinic or imaging follow-up
–30 MRI or non-contrast imaging study
–17 ≥75 days per or post-TACE imaging
–5 received additional treatment
before follow-up
75 procedures excluded:
115 total patients
included in study
Figure 1 Flow Diagram of 348 trans-arterial chemoembolization
(TACE) procedures demonstrating the criteria used to select patients
for this retrospective study
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tiphasic CT and outlined a consistent approach to calculating axial
tumour dimensions and measuring Hounsfield units. After these
teaching sessions, the fellow and medical students jointly worked
through 20 patients together. The medical students, body fellow
and senior staff then reviewed 20 patients independently and the
results were reviewed to verify consistency. The medical students
then reviewed all CT imaging independently. The medical stu-
dents saved the marked images indicating caliper and contrast
enhancement measurements. The UAB CT body fellow (J.Z.) then
independently reviewed all CT studies and confirmed all meas-
urements. A staff radiologist (K.S.) with 19 years of experience
confirmed all quantitative data.
The following baseline tumour characteristics were obtained
from CT images prior to the procedure. Tumor size: consistent
with mRECIST measurements, only axial imaging was used for
tumour size measurements. Electronic calipers were used to
measure the longest diameter of each tumour and the widest
perpendicular measurement in the same image for use in calcu-
lating the cross-sectional tumour diameter. Tumour location:
tumours were labelled central if within 4 cm of the portal vein
bifurcation (Fig. 2a); all others were labelled peripheral (Fig. 2b).
Both axial and coronal imaging was used to calculate the distance
of the tumour from the portal vein bifurcation. Tumour enhance-
ment: each reader measured the Hounsfield units (HU) of the
a b
c d
Figure 2 (a) Axial computed tomography (CT) image demonstrating a central hepatocellular carcinoma (HCC) tumour. Central was defined
as within 4 cm of portal vein bifurcation. (b) Axial CT image demonstrating a peripheral HCC tumour. Peripheral was defined as greater than
4 cm from portal bifurcation. Note also the presence of a clear feeding arterial vasculature. (c) Axial CT image demonstrating arterial phase
tumour enhancement measurement. The arterial phase enhancement was measured as [Hounsfield units (HU) tumour-HU uninvolved
liver]/HU aorta. The HU aorta was used to ‘normalize’ the measured enhancement to the variation observed in contrast bolus administration.
(d) Axial CT image deomonstrating venous phase tumour washout measurement. The venous phase tumour washout was measured as
(HU uninvolved liver – HU tumour). Efforts to ‘normalize’ this measurement to HU vena cava or HU aorta did not significantly alter
the measurement and thus were not used
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tumours in the unenhanced, arterial, portal venous and delayed
(when available) phases. The arterial measurement was normal-
ized to the enhancement in the aorta in the arterial phase (Fig. 2c).
The portal venous washout measurement was normalized to the
enhancement in the normal (uninvolved) liver parenchymal in the
portal venous phase (Fig. 2d). Arterial enhancement was defined
as [(tumor HU arterial phase – tumour HU pre-contrast phase)/
HU aorta arterial phase)]. Portal venous washout was defined as
(HU normal liver parenchyma Portal Venous Phase – HU Tumour
Portal Venous Phase).
The tumour response was measured via the modified response
evaluation criteria in solid tumours (mRECIST). In 2008, the
AASLDmodified the National Cancer Institute RECIST criteria to
unify assessment of a radiographical response for hepatocellular
carcinoma.11 The modified RECIST criteria assess response based
on residual arterial enhancement rather than purely tumour
shrinkage measured by the greatest diameter of the lesion.
Response data are presented for the largest lesion only, herein
referred to as the index lesion. There are four categories of tumour
response according to mRECIST: a complete response, partial
response, stable disease or progressive disease.11 A complete
response is defined as the disappearance of tumour arterial
enhancement. A partial response is defined as at least a 30%
decrease in the diameter of arterial enhancement. For the pur-
poses of the study, the partial response category was subdivided
into a 60–90% and 30–60% response. Subcategorizing > 90%
HCC necrosis is consistent with published literature evaluating
angiographic predictors of TACE-induced tumour necrosis.12
Stable disease is defined as a response that did not fall into the
partial response or progressive disease category. Progressive
disease is defined as growth of at least 20% of the sum of the
longest diameter of the lesions.
TACE protocol
The decision to offer TACE as loco-regional oncological therapy
for patients with HCC was made at the UAB multidisciplinary
liver tumour board. There were two general approaches to TACE.
Single or oligo-HCC tumours, and all patients with compromised
liver function, were generally treated with a Lipiodol-based TACE
whereas multifocal HCC tumours were treated with drug-eluting
beads (DEBS). Lipiodol-based TACE consisted of HCC emboliza-
tion with a mixture of Lipiodol, 50 mg Doxorubicin and 400 mm
Embozene® microspheres (CeloNova BioSciences, Inc., San
Antonio, TX, USA). DEBS TACE consisted of either LC beads
(Biocompatibles, Farnham, UK) or QuadraSpheres®-expanding
microspheres (BioSphere Medical, Roissy-en-France, France).
DEBS were eluted with 50 mg of Doxorubicin. In general,
Lipiodol-based TACE was chosen for tumours that are potentially
possible to treat with tumor-targeted embolization, leaving most
of the non-tumour liver tissue unembolized, especially when the
liver function is compromised. In contrast, non-tumour-targeted
treatment with DEBS TACE was chosen for multifocal HCC
tumours, although non-tumour-targeted treatment was only
offered to patients with preserved liver function.
Statistical analysis
Patient demographics, clinical history, laboratory data and CT
imaging characteristics were collected. Patient and laboratory
variables included age, gender, ethnicity, liver disease aetiology,
alpha-fetoprotein, platelet count,model for end-stage liver disease
(MELD) score and Child–Pugh Score. Patients taking Sorafenib
chemotherapy within 90 days prior to or after the initial TACE
were reported. General TACE data included TACE vehicle (Lipi-
odol or DEBS), repeat TACE within 6 months of initial TACE and
total TACE procedures per patient. Pre-TACE imaging CT vari-
ables included tumour location (peripheral or central, right lobe
versus not), the number of lesions, the size of tumours, the total
diameter of the three largest tumours and HU measurements as
described above. Data collected from post-TACE CT imaging
include HCC tumour necrosis as measured according to
mRECIST criteria.11 To allow common statistical procedures, the
analysis was restricted to examination of the index HCC tumour
that was defined as the largest tumour (if more than one tumour
per patient had been used in the analysis, the common assump-
tion of independent data observations would have been violated).
A two sample t-test was used to compare means between cohorts.
The primary analytic approach for dichotomous variables utilized
chi-square analyses. Logistic regression was used to predict
response. Kaplan–Meier curves were constructed to evaluate
patient survival. Survival probabilities were analysed with the log-
rank test. For all inferences, the probability of a Type I error (a)
was set to 0.05.All analyses were conducted using the SAS 9.2 (SAS
Inc., Cary, NC, USA).
Results
Patient cohorts: favourable response versus poor
response to TACE
Between January 2008 and June 2012, 115 patients received a first
TACE procedure for hepatocellular carcinoma at UAB . The HCC
tumour necrosis distribution as measured by mRECIST is dem-
onstrated in Fig. 3. Roughly half of the patients (n = 59) had a
complete or > 90% HCC tumour necrosis after TACE and are
categorized as a favourable response. The remaining patients (n =
56) had 60–90% or 30–60% tumour necrosis or stable disease or
progressive disease and are categorized as a poor response.
Patient and tumor demographics
The mean age of the TACE cohort was 62 years, 73% were male,
78% Caucasian and 92% were cirrhotic. There were no significant
differences in age, gender, race, cirrhosis etiology, MELD score,
Child’s score or use of Sorafenib within 90 days pre- or post-TACE
between the favourable response and poor response patients.
(Table 1).
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Tumour characteristics
AFP values were not significantly different between the favourable
response and poor response groups. Radiographical data were
recorded for 115 patients with over 210 lesions. The number of
lesions per patient ranged from 1 to greater than 4. More than 4
lesions were appreciated in 16 patients. Fewer tumours were
present in the patients that experienced a favourable response
(1.61 0.87 versus 2.05 1.20,P = 0.0259). The size of the largest
tumour was smaller in the favourable response group (3.7  1.7
versus 5.7  3.5, P < 0.001). Similarly, the total tumour diameter
also was less in the favourable response group (5.6 2.1 versus 7.3
 4.4, P < 0.0001) (Table 2).
TACE intervention
The use of lipiodol was much more common in the favourable
response group compared with the poor response group (76.3%
versus 44.6%, P = 0005). As expected, repeat TACE procedures
within 6 months of the ‘first’ TACE procedure were less common
in the favourable response group compared with the poor
response group (23.7% versus 50.0%, P = 0.0034). There also was
a trend towards fewer total TACE procedures done in the favour-
able response group compared with the poor response group,
although this did not reach significance (P = 0.09) (Table 1).
HCC tumour necrosis
Figure 4 demonstrates the differences in HCC tumour necrosis
between a favourable response and poor response for the pre-
TACE imaging variables. Peripherally located HCC lesions were
more likely to have a favourable response compared with centrally
located lesions [odds ratio (OR) 3.6 95% confidence interval (CI)
1.27, 11.87 P = 0.015]. A smaller maximal dimension of the HCC
tumour was more likely to have a favourable response (OR 0.72
95% CI 0.58, 0.86 P < 0.001). Finally, HCC tumor arterial
enhancement was also significantly associated with a favourable
response to TACE (OR 1.05 95% CI 1.01, 1.10 P = 0.046). Neither
clear feeding vasculature, tumour location in the right lobe versus
other, a single HCC tumour versus multiple and portal vein
washout were significantly associated with a favourable response
to TACE on crude unadjusted analysis (Fig. 4, Table 3).
Multivariable analysis of pre-TACE radiographical
predictors of a favourable response to TACE
The multivariable analysis controlled for the TACE vehicle (lipi-
odol versus DEBS) because this variable was significantly different
between the groups. Only smaller tumour size (OR 0.62 95% CI
0.48, 0.81 P < 0.001) and peripheral location (OR 6.91 95% CI
1.75, 27.29 P = 0.006) were significantly associated with a favour-
able response to TACE. Neither arterial enhancement or portal
venous washout were associated with a > 90% or complete
tumour necrosis in subgroup analyses of centrally located index
HCC tumours <5 cm (P = NS) or peripherally located HCC
tumours <5 cm (P = NS).
Survival
Kaplan–Meier curves were constructed to measure the association
between survival and TACE response. (Fig. 5) No deaths were
appreciated for the first 3 months after the first TACE procedure.
The survival curves converge briefly at 5–6 months, and then
clearly separate. The crude unadjusted survival estimates were not
significantly different between the groups (P = 0.13). After con-
trolling for Child’s score, there was a trend towards improved
survival in the favourable response group although this did not
reach statistical significance (P = 0.08).
Discussion
Tumour characteristics obtained from cross-sectional liver
imaging is utilized in patient selection for TACE. If characteristics
predictive of complete or near complete HCC tumour necrosis
could be identified on pre-therapy imaging, these parameters
would be useful in selecting patients that may benefit from TACE.
However, existing studies provide little conclusive evidence of a
correlation between pre-TACE CT tumour imaging characteris-
tics and a response to therapy. Instead, studies report predictive
variables from TACE angiography and post-TACE imaging that is
associated with HCC tumour necrosis. TACE angiography predic-
tive factors include avid lesion enhancement on angiography
during a TACE procedure,12 the presence of a feeding artery
>0.9 mm12 and a concentration of lipiodol in the tumour.12 Post-
TACE imaging predictive factors include the absence of perfusion
on post-TACE CT,13 increased lipiodol retention14,15 absence of
portal vein thrombosis and arterioportal shunts,16 a decrease in
tumour size12 and a lack of residual enhancement and a decrease
in lesion size measured on post-TACE CT.12 One of the shortcom-
40%
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30%
25%
20%
15%
10%
5%
0%
Complete 90–100% 60–90% 30–60% Stable Progressive
37%
14%
17%
13%
16%
3%
Figure 3 Distribution of hepatocellular carcinoma (HCC) tumour
necrosis after trans-arterial chemoembolization (TACE) as measured
by modified response evaluation criteria in solid tumors (mRECIST)
criteria. *Only data for index lesions are presented and considered
for statistical analysis
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ings of these studies is that the predictive factors are measured
during or after the TACE procedure thus limiting the ability to use
these data in pre-TACE patient selection.
The most important findings from this study are the identifi-
cation of pre-TACE imaging HCC tumour characteristics that are
predictive of tumour necrosis after TACE. We demonstrate that
peripherally located and smaller HCC tumours identified on pre-
TACE CT are more likely to experience complete or > 90%
tumour necrosis after TACE. Centrally located tumours, defined
as less than 4 cm from the portal vein bifurcation, had a very low
rate of complete or > 90% tumour necrosis (5/22, 23%). The
strongest predictive factor of a favourable response to TACE on
multivariable analysis was the peripheral location (OR 6.91). As
expected, smaller tumours were also more likely to experience a
favourable response to TACE (OR 0.62/cm). The effect of tumour
size was clearly demonstrated via the raw data where complete or
> 90% tumour necrosis was observed in 20/30 (67%) tumours <
3 cm, 28/50 (56%) tumours 3–5 cm and 11/35 (31%) tumours
>5 cm. Surprisingly, arterial enhancement was not significantly
associated with HCC tumour necrosis on multivariable analysis,
Table 1 Characteristics of patients with hepatocellular carcinoma treated with transarterial chemoembolization
Cohort Favourable response
(n = 59)a
Poor response
(n = 56)a
Significance
Age (years) 61.7  9.21 62.2  11.7 0.79
Male 69.5% 76.8% 0.38
Race:
African American 18.6% 14.3% 0.94
White 78.0% 78.6%
Other 3.4% 7.1%
Aetiology:b
HCV 57.6% 46.4% 0.23
NASH 22.0% 32.1% 0.22
Laennec's 27.1% 21.4% 0.48
HBV 5.1% 7.1% 0.71
Hemachromatosis 3.4% 1.8% 1.00
MELD Score 11.0  3.5 10.4  3.2 0.33
Child's Score:
A 47.5% 58.9% 0.22
B 49.2% 37.7%
C 3.4% 5.4%
Evidence of portal HTN 0.15
Platelet < 100, cirrhosis 50.9% 51.8%
Platelet > 100, cirrhosis 45.8% 35.7%
Platelet > 100, no cirrhosis 3.3% 12.5%
Sorafenib pre- or post-c 28.8% 39.3% 0.24
TACE vehicle 0.0005
Lipiodol 76.3% 44.6%
Drug-eluting beads 23.7% 55.4%
Repeat TACE within 6 months 23.7% 50.0% 0.0034
Total TACE procedures 0.09
1 64.4% 44.6%
2 28.8% 41.1%
3 or more 6.8% 14.3%
AFP, alpha feto-protein; MELD, model for end-stage liver disease (range 6–40); NASH, non-alcoholic steatohepatitis; HCC, hepatocellular carcinoma;
HTN, hypertension; TACE, transarterial chemoembolization.
aA favourable response is defined as complete or > 90% HCC tumour necrosis. A poor response is defined as < 90% HCC tumour necrosis, stable
disease or disease progression. Tumour necrosis quantified via the modified response evaluation criteria in solid tumours criteria.
bPatients can have more than 1 aetiology of liver disease.
cSorafenib use defined as within 90 day pre- or post-TACE.
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in spite of the rational clinical perception that a HCC tumour that
briskly enhances on CT-arterial phase should be more visible on
TACE arteriogram and hence more likely to uptake embolic mate-
rial and experience tumour necrosis.
Current recommendations for TACE for the oncological man-
agement of HCChave few tumour criteria.2,3 This study is clinically
important because tumour size and location, simply obtained from
CT imaging, can be used to help clinicians decidewhether or not to
Table 2 Baseline hepatocellular carcinoma tumour characteristics
Favourable response
(n = 59)a
Poor response
(n = 56)a
Significance
Tumour number 1.61  0.87 2.05  1.20 0.0259
1 57.6% 46.5%
2 30.5% 23.2%
3 11.9% 21.4%
Size of largest tumour 3.7  1.7 5.7  3.5 <0.001
<3 cm 33.9% 17.9%
3–4.9 cm 49.2% 39.3%
5 cm 16.9% 42.8%
Total tumour diameterb 5.6  2.1 7.3  4.4 0.0001
AFP level
1–15 46.0% 48.9% 0.19
16–500 44.0% 28.8%
>500 10.9% 21.3%
cm, centimeters; AFP, alpha feto-protein; HCC, hepatocellular carcinoma.
aA favourable response is defined as complete or > 90% HCC tumour necrosis. A poor is response defined as <90% HCC tumour necrosis, stable
disease or disease progression. Tumour necrosis quantified via the modified response evaluation criteria in solid tumours criteria.
bTotal tumour diameter of the three largest lesions.
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offer TACE. For example, it may be reasonable to consider TACE
even for patients with mild decompensation if the HCC tumour is
small and peripherally located. A centrally located HCC tumour
over 5 cm, in contrast, has a low likelihood of a favourable response
to TACE and alternative treatment options may be considered.
There was a strong association between TACE vehicle and >
90% or complete HCC tumour necrosis. Clearly there is a selec-
tion bias contributing to this observation. We preferentially use
Lipiodol for targeted embolization for single or oligo-HCC
tumours and in all patients with compromised liver function. In
contrast, DEBS was used for non-targeted multifocal HCC
tumours. The selection bias in our clinical approach, however,
only partially explains the very favourable results seen with Lipi-
odol. We plan to further investigate this observation with a larger
patient cohort to enable controlling for tumour size, number and
central versus peripheral location.
Fewer repeat TACE procedures were performed in the favour-
able response group within 6 months of the ‘first’ TACE.However,
there was no statistically significant association between improved
survival with TACE in the favourable response cohort on crude
unadjusted analysis (P = 0.13). We adjusted the survival for
Child’s score because many of the Child’s B and C patients where
TACE was performed experienced a favourable outcome but their
survival may be limited by underlying liver dysfunction. However,
only a statistical trend emerged between survival and favourable
response to TACE (P = 0.08) when controlling for Child’s score.
Examination of the Kaplan–Meier figure reveals that the post-
TACE survival curves merge at 5–6 months and then separate.
Table 3 Univariate versus multivariable analyses of pre-TACE CT imaging predictors of a > 90% or complete tumour necrosis as measured
by mRECIST criteria
Univariate Multivariable
Odds Ratio 95% CI P-value Odds Ratio 95% CI P-value
Peripheral HCC locationa 3.60 (1.27, 11.87) 0.015 6.91 (1.75, 27.29) 0.006
Clear feeding vasculature 0.95 (0.45, 1.99) 0.881 1.12 (0.40, 3.12) 0.832
Lobe (right versus other) 0.97 (0.41, 2.31) 0.948 1.21 (0.39, 3.73) 0.739
Maximal tumour dimension 0.72 (0.58, 0.86) <0.001 0.62 (0.48, 0.81) <0.001
Single lesion 1.57 (0.75, 3.30) 0.231 1.46 (0.56, 3.84) 0.441
Arterial phase enhancementb 1.05 (1.01, 1.10) 0.046 1.03 (0.96, 1.09) 0.441
Portal venous washoutc 1.56 (0.58, 4.35) 0.382 1.03 (0.26, 4.04) 0.970
TACE, trans-arterial chemoembolization; CT, computed tomography; mRECIST, modified response evaluation criteria in solid tumours;
HCC, hepatocellular carcinoma.
aDefined as > 4 cm from the portal vein bifurcation.
bDefined as [(Tumour HU Arterial Phase – Tumour HU Pre-Contrast Phase)/ HU Aorta Arterial Phase], where HU = Hounsfield Units.
cDefined as (HU Uninvolved Liver Parenchyma Portal Venous Phase – HU HCC Tumor Portal Venous Phase), where HU = Hounsfield Units.
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Figure 5 Kaplan–Meier curve comparing overall survival in patients with a favourable response compared with a poor response to
trans-arterial chemoembolization (TACE). Overall survival measured from the time of the first TACE procedure. *A favourable response is
defined as complete or > 90% HCC tumour necrosis. A poor response is defined as < 90% HCC tumour necrosis, stable disease or disease
progression. Tumour necrosis quantified via the modified response evaluation criteria in solid tumours criteria
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From a statistical standpoint, survival curves that merge or cross
cannot be significantly different thus explaining why seemingly
divergent survival trajectories may not be statistically different.
There are few studies in the literature examining the association
between the response rate measured by mRECIST and overall
survival after TACE. A randomized controlled trial by Llovet et al.
found that response sustained at 6 months post-TACE correlated
with improved survival.17 Other studies show improved survival
with a reduction in serum AFP after TACE,18 multiple TACE pro-
cedures8 and early-stage tumours.19
The main limitation of this study is its retrospective design and
inherent practice patterns that may bias the data. For example,
UAB has a more liberal policy for offering TACE to patients with
liver dysfunction as long as the patient has a good functional
status, no severe coagulopathy or medically refractory ascites.
Over half of the favourable response group was Child’s B or C
cirrhotics, which undoubtedly leads to underestimation of TACE
oncological survival advantage. In comparison, a previous meta-
analysis proving the survival benefit of TACE included studies
where Child’s A patients accounted for 70–100% of reported
cases.1 The survival analysis was also limited by the small sample
size raising the possibility of a type 2 statistical error. Another
difference observed in our data is a higher objective radiographi-
cal response to TACE compared with most previous studies in the
literature. Bruix et al. 20,21 summarized data from randomized pro-
spective studies and reported a 15–55% TACE HCC tumour
response whereas we observed an 81% response in this study.
In summary, we demonstrate that peripherally located and
smaller HCC tumours identified on pre-TACE imaging are inde-
pendent predictors of complete or >90 HCC tumour necrosis.
These findings may be important in patient selection for TACE.
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